UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
___________________
FORM
8-K
__________________________
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported) March 14, 2005
NOVADEL
PHARMA INC.
(Exact
Name of Registrant as Specified in Its Charter)
__________________________
| |
|
|
|
|
|
Delaware |
|
001-32177 |
|
22-2407152 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File No.) |
|
(I.R.S.
Employer
Identification
No.)
|
25
Minneakoning Road
Flemington,
New Jersey 08822
(Address
of principal executive offices) (Zip Code)
(908)
782-3431
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
__________________________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
|
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
¨ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item
7.01. Regulation
FD Disclosure.
On March
14, 2005 the Company issues a press release to announce that NovaDel Pharma Inc.
would present at the Investing & Partnering in Biotech Forum. The Company
hereby incorporates by reference herein the information set forth in the slide
presentation to be presented at the forum, a copy of which is attached hereto as
Exhibit 99.1. The full text of the press release is set forth in Exhibit 99.2.
Item
8.01. Other
Events
On March
16, 2005, the Company issued a press release to announced positive results from
a pilot pharmacokinetic trial in healthy human subjects that was conducted using
it’s proprietary lingual spray technology to deliver ondansetron hydrochloride
--- the active ingredient marketed under the brand name Zofran® by
GlaxoSmithKline for the treatment of chemotherapy-induced nausea and vomiting.
The full text of the press release is set forth in Exhibit 99.3
hereto.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits.
| 99.1 |
Slide
Presentation used at March 16, 2005 Investing & Partnering in Biotech
Forum. |
| 99.2 |
Press
release dated March 14, 2005, titled “NovaDel Pharma Inc. to Present at
the Investing & Partnering in Biotech
Forum.” |
| 99.3 |
Press
Release dated March 16, 2005, titled “NovaDel
Pharma Inc. Announces Positive Pharmacokinetic Study Results of
Ondansetron Lingual Spray.” |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
NovaDel Pharma
Inc. |
| |
|
|
|
|
|
|
By: /s/ Jean W.
Frydman |
| |
Name: Jean
W. Frydman |
| |
Title: Vice
President, General Counsel |
| |
and Corporate Secretary |
| |
|
| Date: March 16, 2005 |
|